Breaking News

Momentum Biotechnologies Acquires OmicScouts

Gains access to a portfolio of well-validated proteomic assays that enhance and extend its existing service offerings.

Momentum Biotechnologies, a contract research organization (CRO) specializing in mass spectrometry-based drug discovery, has acquired OmicScouts GmbH, a Munich-based CRO and leader in the field of mass spectrometry-based proteomics. Moving forward, the company will operate as OmicScouts, a Momentum Biotechnologies Company. With this transaction, Momentum gains access to a portfolio of well-validated proteomic assays that enhance and extend its existing service offerings, enabling clients to s...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters